Table 3. Therapies combining fludarabine... | American Society of Hematology

Table 3.

Therapies combining fludarabine plus cyclophosphamide with rituximab or oblimersen.

Reference	Regimen	N	Median age, y	Advanced stage, %*	ANC, toxicity grade 3–4, %	CR, %	OR, %	PFS, mo
*Rai III-IV
**Binet C
†Only CTC grade 4
‡Time to treatment failure
FC indicates fludarabine and cyclophosphamide; FCR, FC plus rituximab; FCO, FC plus oblimersen; ANC, absolute neutrophil count.
First line
Hallek³²	FC	409	61	31	21	23	85	32
	FCR	408	61	31	34	44	92	43
Second line
O’Brien⁴⁷	FC	121	63	50	11†	3	45	9
	FCO	120	63	45	7†	9	41	6
Robak³³	FC	272	62	NA	40	13	58	21‡
	FCR	274	62	NA	42	24	70	31‡

Reference	Regimen	N	Median age, y	Advanced stage, %*	ANC, toxicity grade 3–4, %	CR, %	OR, %	PFS, mo
*Rai III-IV
**Binet C
†Only CTC grade 4
‡Time to treatment failure
FC indicates fludarabine and cyclophosphamide; FCR, FC plus rituximab; FCO, FC plus oblimersen; ANC, absolute neutrophil count.
First line
Hallek³²	FC	409	61	31	21	23	85	32
	FCR	408	61	31	34	44	92	43
Second line
O’Brien⁴⁷	FC	121	63	50	11†	3	45	9
	FCO	120	63	45	7†	9	41	6
Robak³³	FC	272	62	NA	40	13	58	21‡
	FCR	274	62	NA	42	24	70	31‡